CN113301955A - 治疗掌跖脓疱症的抗il-36r抗体 - Google Patents

治疗掌跖脓疱症的抗il-36r抗体 Download PDF

Info

Publication number
CN113301955A
CN113301955A CN201980087043.9A CN201980087043A CN113301955A CN 113301955 A CN113301955 A CN 113301955A CN 201980087043 A CN201980087043 A CN 201980087043A CN 113301955 A CN113301955 A CN 113301955A
Authority
CN
China
Prior art keywords
week
amino acid
acid sequence
seq
ppp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980087043.9A
Other languages
English (en)
Chinese (zh)
Inventor
C·托马
P·鲍姆
J·拉马尔
S·J·帕杜拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Publication of CN113301955A publication Critical patent/CN113301955A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CN201980087043.9A 2018-12-27 2019-12-20 治疗掌跖脓疱症的抗il-36r抗体 Pending CN113301955A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862785316P 2018-12-27 2018-12-27
US62/785,316 2018-12-27
US201962815431P 2019-03-08 2019-03-08
US62/815,431 2019-03-08
US201962891464P 2019-08-26 2019-08-26
US62/891,464 2019-08-26
PCT/EP2019/086521 WO2020136101A1 (en) 2018-12-27 2019-12-20 Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Publications (1)

Publication Number Publication Date
CN113301955A true CN113301955A (zh) 2021-08-24

Family

ID=69190739

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980087043.9A Pending CN113301955A (zh) 2018-12-27 2019-12-20 治疗掌跖脓疱症的抗il-36r抗体

Country Status (14)

Country Link
US (3) US20200207862A1 (https=)
EP (1) EP3902604A1 (https=)
JP (1) JP2022515480A (https=)
KR (1) KR20210119407A (https=)
CN (1) CN113301955A (https=)
AU (1) AU2019416727A1 (https=)
BR (1) BR112021010789A2 (https=)
CA (1) CA3124996A1 (https=)
CL (1) CL2021001685A1 (https=)
IL (1) IL284259A (https=)
MX (1) MX2021007807A (https=)
PH (1) PH12021551540A1 (https=)
TW (1) TW202037604A (https=)
WO (1) WO2020136101A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016168542A1 (en) 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CA3093692A1 (en) 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis
BR112021016198A2 (pt) 2019-03-08 2021-11-03 Boehringer Ingelheim Int Formulações de anticorpo anti-il-36r
EP4182022A1 (en) * 2020-07-17 2023-05-24 Boehringer Ingelheim International GmbH Anti-il-36r antibodies for the treatment of neutrophilic dermatoses
US20220119538A1 (en) * 2020-09-30 2022-04-21 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
CA3209006A1 (en) * 2021-03-04 2022-09-09 Boehringer Ingelheim International Gmbh Methods for the treatment of gpp
BR112023017717A2 (pt) 2021-05-03 2024-01-09 Boehringer Ingelheim Int Método para produção de espesolimabe
CA3218343A1 (en) * 2021-05-12 2022-11-17 Anaptysbio, Inc. Antibody composition
EP4370550A1 (en) * 2021-07-12 2024-05-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
KR20250122528A (ko) * 2022-12-23 2025-08-13 아이코사백스, 인크. 메타뉴모바이러스 융합(f) 단백질에 대한 항체 및 그 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
KR102038310B1 (ko) 2011-11-16 2019-11-01 베링거 인겔하임 인터내셔날 게엠베하 항 ｉｌ-36ｒ 항체
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
WO2016168542A1 (en) * 2015-04-15 2016-10-20 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (il-36r)
CN107660155B (zh) 2015-04-24 2021-02-02 艾斯曲尔医疗公司 药剂输送装置的子组件和药剂输送装置
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
JP6654773B2 (ja) * 2015-12-25 2020-02-26 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
CA3093692A1 (en) * 2018-03-14 2019-09-19 Boehringer Ingelheim International Gmbh Use of anti-il-36r antibodies for treatment of generalized pustular psoriasis

Also Published As

Publication number Publication date
US20230131364A1 (en) 2023-04-27
TW202037604A (zh) 2020-10-16
MX2021007807A (es) 2021-08-11
JP2022515480A (ja) 2022-02-18
PH12021551540A1 (en) 2022-02-21
BR112021010789A2 (pt) 2021-08-31
WO2020136101A1 (en) 2020-07-02
EP3902604A1 (en) 2021-11-03
US20230115617A1 (en) 2023-04-13
CA3124996A1 (en) 2020-07-02
AU2019416727A1 (en) 2021-07-22
IL284259A (en) 2021-08-31
US20200207862A1 (en) 2020-07-02
CL2021001685A1 (es) 2022-02-18
KR20210119407A (ko) 2021-10-05

Similar Documents

Publication Publication Date Title
JP7673168B2 (ja) 汎発性膿疱性乾癬の処置のための抗ｉｌ－３６ｒ抗体の使用
US20230115617A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
CN118141914A (zh) 用于通过施用il-4r拮抗剂来预防或治疗变态反应的方法
US20150291689A1 (en) Compositions and Methods for Treating Rheumatoid Arthritis
CN112955222A (zh) 用于治疗患有类风湿性关节炎的个体的方法和组合物
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
US20240352137A1 (en) Methods for the treatment of gpp
US20220010022A1 (en) Anti-il-36r antibodies for the treatment of atopic dermatitis
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
EA046186B1 (ru) Применение антител к il-36r для лечения генерализованного пустулёзного псориаза
CN116963776A (zh) 治疗gpp的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination